International Journal of Clinical Case Reports 2024, Vol.14, No.5, 253-261 http://medscipublisher.com/index.php/ijccr 261 Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M., Bonaca M.P., Mosenzon O., Kato E.T.,. Cahn A, Bhatt D.L., Leiter L.A., McGuire D.K., Wilding J.P.H., and Sabatine M.S., 2019, Comparison of the effects of GLP-1 receptor agonists and SGLT2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation, 139: 2022-2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868 PMID: 30786725 Zinman B., Bhosekar V., Busch R., Holst I., Ludvik B., Thielke D., et al., 2019, Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial, The Lancet Diabetes and Endocrinology, 7(5): 356-367. https://doi.org/10.1016/S2213-8587(19)30066-X PMID: 30833170
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==